<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580995</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-001C-10F</org_study_id>
    <nct_id>NCT01580995</nct_id>
  </id_info>
  <brief_title>Herpes Simplex Type 1 Suppression in Hepatitis C</brief_title>
  <acronym>HSV1/HCV</acronym>
  <official_title>HSV-1 Suppression in HCV Infected Veterans Who Are Seronegative for HSV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of valacyclovir in patients who have
      chronic hepatitis C, antibodies to herpes simplex type 1 infection but do not have antibodies
      to herpes simplex type 2 infection. Herpes simplex type 1 infection commonly causes cold
      sores or fever blisters, also known as herpes labialis, but most persons do not have any
      symptoms at all. Valacyclovir is a medication which is approved by the Food and Drug
      administration to treat herpes labialis. Valacyclovir has not been approved to treat chronic
      hepatitis C infection.

      The study will take 16 weeks. Participants will be assigned to take either the study drug,
      valacyclovir, or a sugar pill that looks exactly like valacyclovir. The researchers and
      patients will not know which medication they are receiving. Study visits will occur every two
      weeks and will take approximately 30-45 minutes. All study visits will occur at the G.V.
      Sonny Montgomery VA Medical Center in Jackson, Mississippi.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blind placebo-controlled clinical trial evaluating the effect of
      500 mg valacyclovir twice daily on HCV viral load in HSV-1/HCV co-infected patients
      seronegative for HSV-2. Potential participants will be recruited from the Jackson VAMC viral
      hepatitis clinics. Eligible individuals will be invited to enroll in the study in a
      noncoercive manner. Study personnel will obtain full informed consent.

      Using a computer generation randomization scheme, patients will be randomized 1:1 in blocks
      of 4 to receive valacyclovir 500 mg po twice daily or matching placebo. Patients will be
      counseled on the signs and symptoms of herpes labialis and genital herpes and complete a
      questionnaire to document medical/social history. Venipuncture will be performed every four
      weeks (i.e., at every other follow-up visit) to monitor complete blood cell count, liver
      function tests, serum levels of hepatitis C RNA and Herpeselect IgG HSV-2 ELISA. A
      de-identified baseline serum sample will be collected and stored in VA approved research
      space for future testing. At each visit, pill-count and tolerability of medications will be
      assessed. Patients will be asked about signs or symptoms of genital herpes. Data will be kept
      in a study chart labeled with the participant's coded study number in a locked office.
      Information from each study visit will be recorded into the chart by the PI or RA and entered
      into an encrypted database on a secure VA server. Baseline characteristics of the placebo and
      intervention group will be compared using appropriate parametric tests. HCV viral loads will
      be log10 transformed and analyzed using an intention to treat model.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HCV RNA Viral Load</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Measure change in HCV RNA viral load in treatment group as compared with placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valacyclovir 500 mg po bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>Valacyclovir 500 mg po bid</description>
    <arm_group_label>Valacyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C infection with a detectable HCV RNA in the serum on two occasions,
             6 months apart

          -  Focus HSV-2 IgG negative and Focus HSV-1 IgG positive, using manufacturer's cut-offs

        Exclusion Criteria:

          -  Antiherpes or immunomodulatory therapy during the past 30 days,

          -  HIV or chronic hepatitis B infection,

          -  Decompensated liver disease (ascites, hepatic encephalopathy, coagulopathy,
             jaundice/icterus),

          -  Creatinine clearance &lt;50 ml/min.,

          -  Female subject who is pregnant or nursing,

          -  Gastrointestinal disorder which might result in malabsorption of valacyclovir,

          -  History of erythema multiforme major, thrombotic thrombocytopenia purpura or hemolytic
             uremic syndrome,

          -  Allergy to valacyclovir or related drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary J Burton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>G.V. (Sonny) Montgomery VA Medical Center, Jackson, MS</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <results_first_submitted>June 13, 2016</results_first_submitted>
  <results_first_submitted_qc>August 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 21, 2016</results_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valacyclovir</title>
          <description>Valacyclovir 500 mg po bid
Valacyclovir: Valacyclovir 500 mg po bid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo twice daily
Placebo: Placebo tablet twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valacyclovir</title>
          <description>Valacyclovir 500 mg po bid
Valacyclovir: Valacyclovir 500 mg po bid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo twice daily
Placebo: Placebo tablet twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="2"/>
                    <measurement group_id="B2" value="57" spread="3"/>
                    <measurement group_id="B3" value="56" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HCV RNA Viral Load</title>
        <description>Measure change in HCV RNA viral load in treatment group as compared with placebo</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>patients who completed 12 weeks of follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Valacyclovir 500 mg po bid
Valacyclovir: Valacyclovir 500 mg po bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo twice daily
Placebo: Placebo tablet twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HCV RNA Viral Load</title>
          <description>Measure change in HCV RNA viral load in treatment group as compared with placebo</description>
          <population>patients who completed 12 weeks of follow up</population>
          <units>log(IU/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".24" spread=".20"/>
                    <measurement group_id="O2" value=".08" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Valacyclovir</title>
          <description>Valacyclovir 500 mg po bid
Valacyclovir: Valacyclovir 500 mg po bid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo twice daily
Placebo: Placebo tablet twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Jane Burton</name_or_title>
      <organization>VAORD</organization>
      <phone>6013624471</phone>
      <email>mary.burton2@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

